We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
High-dose cisplatin in hypertonic saline.
- Authors
Ozols, Robert E.; Corden, Brian J.; Jacob, Joan; Wesley, Margaret N.; Ostchega, Yechian; Young, Robert C.; Ozols, R F; Corden, B J; Jacob, J; Wesley, M N; Ostchega, Y; Young, R C
- Abstract
To overcome the dose limiting toxicity of cisplatin we have administered high-dose cisplatin (200 mg/m2 body surface area in five divided daily doses with each dose administered in 250 mL of 3% saline) together with extensive hydration (250 mL/h normal saline with 20 meq KCI/L). In 17 previously untreated patients with poor prognosis nonseminomatous testicular cancer, 8 with tumor-associated obstructive uropathy, there was no statistically significant decrease in creatinine clearance or elevation of serum creatinine after three to four cycles of a high-dose cisplatin in combination chemotherapy regimen. High-dose cisplatin in combination with vinblastine, bleomycin, and VP-16 produced an 88% complete response rate in these high-risk patients who are characterized primarily by the presence of advanced bulky lung and abdominal disease. Six patients with ovarian cancer who had a relapse after treatment with standard dose cisplatin regimens were treated with high-dose cisplatin and three partial responses were seen. Four patients had no adverse effects on renal function whereas 2 patients had transient elevations in serum creatinine (4 to 5 mg/dL). Hypertonic saline did not provide protection against the nonrenal toxicities of cisplatin.
- Subjects
CISPLATIN; TOXICOLOGY; HYDRATION; ANTINEOPLASTIC agents; BLEOMYCIN; CELL lines; CREATININE; ETOPOSIDE; FLUID therapy; KIDNEY diseases; OVARIAN tumors; PROGNOSIS; TESTIS tumors; VINBLASTINE; HYPERTONIC saline solutions
- Publication
Annals of Internal Medicine, 1984, Vol 100, Issue 1, p19
- ISSN
0003-4819
- Publication type
journal article
- DOI
10.7326/0003-4819-100-1-19